Huntsville's Bold Bet: Unpacking the Multi-Billion-Dollar Eli Lilly Investment

Wegovy in Vials? Novo Nordisk's Strategic Shift to Boost Supply and Challenge Eli Lilly

The Weight-Loss Drug Wars: Novo Nordisk Eyes Vials for Wegovy in High-Stakes Battle

GLP-1 Medications: Separating Hype from Health with Expert Insights

Hims & Hers Hits the Brakes: Generic Wegovy Plans Abandoned Amidst GLP-1 Market Shifts

Eli Lilly's Ascendant Journey: Why Its Premium Price Tag Might Just Be Worth It

Novo Nordisk: The High-Stakes Balancing Act Between Price and Scale

The Market's Two Minds: Lilly's High-Stakes Game Meets Housing's Quiet Comeback

Eli Lilly CEO Sees Medicare Support as Game-Changer for New Oral Obesity Pill

A New Era in Obesity Treatment: The Rise of Oral Weight-Loss Solutions

The Pharmaceutical Frontier: Navigating Breakthroughs, Billions, and Bitter Debates

A $6 Billion Bet on Indiana: Eli Lilly's Massive Expansion Promises Thousands of Jobs

A Collective Sigh of Relief: Eli Lilly Breaks Nine-Day Losing Streak

The Great Unbundling: Why Weight Loss Drug Prices Are Finally Coming Down

Eli Lilly's Jaypirca Secures Full FDA Approval, Offering New Hope for Certain Blood Cancers

Eli Lilly's Zepbound Gets a Significant Price Drop: What It Means for Patients and the Market

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

Eli Lilly Slashes Zepbound Prices Amid Political Pressure and Trump's Claims

Unanimous Picks: Why Top Funds Are Doubling Down on These Six Stocks

A New Era for Weight Loss: The Revolution of GLP-1 Pills and Monthly Shots

Eli Lilly's Short-Term Horizon: A Look at Market Expectations

Modern Health's Crossroads: Unpacking Ultra-Processed Food Warnings and the Egg Freezing Debate

Eli Lilly's Trillion-Dollar Triumph: Reshaping the Pharma Landscape

The Trillion-Dollar Bet: How Eli Lilly is Reshaping the Global Economy

Eli Lilly's Trillion-Dollar Triumph: A New Chapter in Pharmaceutical History

The Pharma Giants' Bold Leap: Novo Nordisk and Eli Lilly Eyeing Direct Sales of Obesity Drugs to Employers

Wegovy's Reckoning: Novo Nordisk's CEO Digs In as the Weight Loss Market Heats Up

The $1,000 Question: Where Savvy Investors Are Parking Their Money for Tomorrow's Gains

Julianne Moore's Enduring Crusade: Beyond the Screen, Forging a Path to Brain Health

A Glimmer of Hope: Eli Lilly's Bold Leap into Gene Therapy for Blinding Eye Diseases

The GLP-1 Gold Rush: Will Trump Rewrite the Rules for Eli Lilly and Novo Nordisk?

The Billion-Dollar Battle for the Future of Weight Loss: Pfizer Jumps into the Ring

The Great Weight-Loss Gambit: Pfizer Jumps into the Billion-Dollar Battle for Obesity Treatment Supremacy

The Great GLP-1 Gold Rush: Pfizer Jumps into the Billion-Dollar Battle for Weight Loss Dominance

The Great Weight-Loss Race: Pfizer's Billion-Dollar Gambit to Conquer Obesity

The Lilly Lull: Why a Minor Dip Might Be Just a Blip in a Pharmaceutical Powerhouse's Journey

The Great Prescription Price Shake-Up: Could Trump's Bold Plan Reshape US Healthcare?

The Price of Progress? Unpacking the Billion-Dollar Buzz Around America's New Weight-Loss Fixes

The GLP-1 Gambit: Pharma Giants, Trump, and the High Stakes of Drug Prices